What Is KPV? A Research Guide

What is KPV?

KPV is a research peptide supplied by Pepology strictly for laboratory and research use only. It is not intended for use in humans or animals, and nothing in this guide describes any such use. The purpose here is simply to explain what the molecule is at a research level and why it draws laboratory interest.

At a structural level, KPV is a short tripeptide. Its name is drawn from the single-letter codes of its three amino acids: lysine (K), proline (P) and valine (V), joined in the sequence Lys-Pro-Val. Because it contains only three residues, it is one of the smaller peptides in the research category and is far more compact than the longer chains many laboratories work with.

KPV is derived from a naturally occurring signalling molecule. It corresponds to the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), specifically residues 11 to 13 of that larger sequence. In the research literature it is therefore often written as alpha-MSH(11-13). This relationship to a well characterised parent hormone is one reason the fragment has been studied on its own.

You can view the product page here: [View KPV](/shop/6a7d18fffd96924e88327fb4).

The molecule at a glance

For orientation, the core structural facts that researchers reference are straightforward and well established in the literature:

• Class: a short peptide fragment, categorised in research contexts as a melanocortin-derived tripeptide.
• Sequence: lysine-proline-valine (Lys-Pro-Val), abbreviated KPV.
• Parent molecule: the C-terminal region of alpha-melanocyte-stimulating hormone (alpha-MSH), residues 11 to 13, hence the label alpha-MSH(11-13).
• Form: typically supplied as a lyophilised (freeze-dried) powder for handling in a laboratory setting.

Why researchers study KPV

Research interest in KPV centres on the inflammatory signalling pathways it has been associated with in preclinical and laboratory work. It sits in the Recovery research category on the Pepology catalogue because the pathways investigators connect it with are the same ones studied in models of tissue inflammation and repair.

A recurring theme in the published literature is that KPV has been investigated as a way to isolate some of the signalling interest of its parent alpha-MSH separately from the pigment-related activity that the full-length hormone shows. This separation of properties is a large part of why the isolated fragment became a subject of study rather than the whole hormone.

It is important to frame this correctly. These are observations from cell-culture systems and animal disease models, reported by researchers exploring mechanism. They describe how the molecule appears to behave in a controlled preclinical setting, not any effect, benefit or outcome in a person or animal.

Preclinical pathways and mechanisms of interest

Much of the mechanistic work on KPV in the laboratory focuses on intracellular signalling associated with the inflammatory response. Several themes appear repeatedly across the research base.

• NF-kappaB signalling. KPV has been studied in cultured cells for its association with the NF-kappaB pathway, a central regulator of the transcription of inflammatory genes.
• MAP-kinase signalling. Related preclinical work has examined the peptide in the context of mitogen-activated protein kinase cascades, another set of pathways involved in cellular inflammatory signalling.
• Pro-inflammatory cytokine output. In epithelial and immune-cell models, researchers have characterised how the peptide relates to the production of pro-inflammatory cytokines and chemokines.
• PepT1-mediated transport. A distinctive strand of the literature examines the peptide transporter PepT1 as a route by which KPV is taken up into intestinal epithelial and immune cells, a mechanism that is somewhat unusual for a molecule of this type.
• Receptor-independent activity. Some studies in colitis models describe signalling that appears to be at least partly independent of classical melanocortin receptor 1 (MC1R) activity, which has kept researchers interested in exactly how the fragment behaves at a molecular level.

The models it appears in

The preclinical models in which KPV has been characterised map closely to those signalling pathways. In cell culture, researchers have worked with epithelial and immune cell lines challenged with inflammatory stimuli in order to observe how the peptide relates to downstream signalling markers.

In whole-organism preclinical work, the fragment has featured in rodent models of intestinal inflammation, which is where much of the PepT1 transport interest arose, and in other models of tissue injury where inflammatory signalling is a key readout. Across these settings the common thread is mechanism: investigators are mapping how a very small peptide interacts with well studied inflammatory pathways.

None of this constitutes evidence of a use, treatment, therapy or outcome in people or animals. It is a body of mechanistic research that characterises the molecule, and it is the reason KPV is offered as a research compound rather than anything else.

How to verify quality

For any research peptide, the single most useful document is the certificate of analysis, or CoA. It is the laboratory record that ties a specific production batch to the analysis performed on it, and it is the primary evidence that what is in the vial matches the label.

Every Pepology batch is tested independently by Novagen Laboratories, a third-party lab with no stake in the sale. Independent testing matters because a certificate issued by the seller alone asks you to trust the vendor to report on their own product. A named third-party laboratory removes that conflict of interest.

The types of analysis a research buyer should expect to see described on a CoA include identity confirmation, which checks the molecule is the sequence the label claims, and a purity assessment, commonly by high-performance liquid chromatography (HPLC), which reports how much of the material is the target peptide. Speak in terms of the methods rather than fixating on any single number, and always cross-check the certificate against the physical vial.

A short verification checklist:

• Find the lot or batch number on the certificate, then confirm it matches the number printed on the vial you received. The certificate only describes that one production run.
• Confirm the compound identity on the certificate reads KPV and that an identity method is stated.
• Look for a purity assessment by a stated method such as HPLC, described clearly rather than merely asserted.
• Check that the certificate is issued under the name of an independent third-party laboratory, in this case Novagen Laboratories, not self-issued by the seller.
• Verify the certificate independently rather than taking a printed copy at face value: [Verify a batch certificate](/verify).

Sourcing KPV in Australia with confidence

Pepology is an Australian retailer of research peptides, owned and operated on the Gold Coast. Sourcing a research compound domestically means it ships within Australia rather than crossing a border, and it means you are dealing with a local operation that stands behind the batch documentation it provides.

When you buy KPV from Pepology, the batch has been third-party tested by Novagen Laboratories and comes with a certificate of analysis you can verify for yourself. That combination, a named independent lab plus a certificate tied to the exact lot in your hands, is the practical standard a careful research buyer should hold any supplier to.

To be completely clear, KPV and every other compound in the range are supplied strictly for laboratory and research use only. They are not for human or animal use.

You can view the product here: [View KPV](/shop/6a7d18fffd96924e88327fb4), or [Browse all research peptides](/shop) to see the wider catalogue.

View KPV Browse all research peptides